Sponsor content

apceth pioneers engineered cell therapies for use in the clinic

apceth’s innovative modular proprietary technology provides versatility and endless possibilities for generating specific targeted cell-based therapies. To download the full article, please sign in.

Go to the profile of Apceth GmbH & Co KG
Nov 05, 2015
1
Upvote 1
Page of
Go to the profile of Apceth GmbH & Co KG

Apceth GmbH & Co KG

We are a clinical stage biopharmaceutical company, based in Munich, developing first-in-man, first-in-class, targeted therapies for cancer, inflammation and tissue regeneration. Our proprietary platform technology is based on next generation engineered cell-based therapeutics, which offer considerable advantages over existing technologies. Our lead product is already in Phase II, for the treatment of gastrointestinal tumors. In addition, we provide our know-how, expertise and GMP-certified facilities to offer development, optimisation, scale up and GMP manufacturing services to industry and academic partners around the world. apceth was one of the very first companies in Germany to receive a manufacturing license in 2010 for pharmaceutical production of somatic cell therapeutics and tissue procurement according to the German Medicines Act (AMG).

Comments are disabled